Raymond James keeps a Strong Buy rating on Biohaven (BHVN) shares following competitor Xenon Pharmaceuticals’ (XENE) top-line Phase 3 readout for Kv7 modulator azetukalner showing efficacy in-line with expectations with a meaningful safety disadvantage, giving opakalim room to differentiate. The firm believes the results continue to highlight an opportunity for opakalim, or BHV-7000, which has shown meaningful evidence of efficacy with better safety and tolerability. Raymond James expects Biohaven to present topline results from the first pivotal trial for opakalim, testing a 25 mg and 50 mg dose, in the second half of 2026, which will more concretely establish the target product profile, and would be a buyer into this event.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Biohaven fractionally lower after Xenon reports azetukalner Phase 3 hit target
- Controversial Prasad leaving FDA, NYT reports
- Biohaven price target lowered to $10 from $11 at H.C. Wainwright
- Biohaven price target lowered to $14 from $15 at BofA
- Maintaining Hold on Biohaven: Encouraging Early Signals but Awaiting Placebo-Controlled Data and Funding Clarity